Apart from targeting the BCR–Abl oncoprotein and c‐KIT (CD117), which are driving kinases in CML and GISTs, respectively, imatinib also blocks PDGFRβ 51. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.